Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;17(12):982-7.
doi: 10.1007/s12094-015-1436-2. Epub 2015 Nov 25.

Biliary tract cancers: SEOM clinical guidelines

M Benavides  1 , A Antón  2 , J Gallego  3 , M A Gómez  4 , A Jiménez-Gordo  5 , A La Casta  6 , B Laquente  7 , T Macarulla  8 , J R Rodríguez-Mowbray  9 , J Maurel  10
Affiliations

Biliary tract cancers: SEOM clinical guidelines

M Benavides et al. Clin Transl Oncol. 2015 Dec.

Abstract

Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.

Keywords: Biliary tract cancer; Cholangiocarcinoma; Gall bladder cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Diagnostic work-up and treatment guidelines
See this image and copyright information in PMC

References

    1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229. doi: 10.1053/j.gastro.2013.10.013. - DOI - PMC - PubMed
    1. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–1289. doi: 10.1016/j.jhep.2014.01.021. - DOI - PubMed
    1. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4:695–706. doi: 10.1038/nrc1429. - DOI - PubMed
    1. Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary care of patients with intrahepatic cholangiocarcinoma: updates in management. Gastroenterol Res Pract. 2015;2015:1–14. doi: 10.1155/2015/860861. - DOI - PMC - PubMed
    1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321. doi: 10.1002/hep.22310. - DOI - PMC - PubMed